Evaluation of BTS 67 582, a novel antidiabetic agent, in normal and diabetic rats
- 1 March 1997
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 120 (6), 1135-1143
- https://doi.org/10.1038/sj.bjp.0701019
Abstract
1. The effect of BTS 67 582, a novel antidiabetic agent, has been evaluated on plasma glucose and plasma insulin in normal and streptozotocin-induced diabetic rats. 2. BTS 67 582 (3 to 300 mg kg-1, p.o.) caused a dose- and time-dependent reduction in plasma glucose and an increase in plasma insulin in both fasted and glucose-loaded normal rats. The ED50 for the glucose lowering effect of BTS 67 582 in fasted rats was 37.6, 18.4 and 18.5 mg kg-1 at 1, 2 and 4 h after administration respectively. 3. In streptozotocin-induced (50 mg kg-1, i.v.) diabetic rats, BTS 67 582 (37-147 mg kg-1, p.o.) caused significant reductions of plasma glucose following a glucose load, whereas glibenclamide (100 mg kg-1, p.o.) was ineffective. BTS 67 582 significantly increased plasma insulin compared to controls whereas glibenclamide did not. 4. BTS 67 582 did not displace [3H]-glibenclamide from its binding sites in rat brain, guinea-pig ventricle or the HIT-T15 insulinoma beta-cell line. BTS 67 582 does not therefore appear to modulate its action via an effect on the 'sulphonylurea' receptor. 5. In fasted rats, the glucose lowering effect of BTS 67 582 (100 mg kg-1 p.o.) and glibenclamide (1 mg kg-1, p.o.) were antagonized by diazoxide (30 mg kg-1, i.p.). In addition BTS 67 582, like glibenclamide, caused a dose-dependent rightward shift of cromakalim-induced relaxation of noradrenaline precontracted rat aortic strips, suggesting the involvement of KATP channels. 6. In summary, BTS 67 582 produces a blood glucose-lowering effect in normal and streptozotocin-induced diabetic rats associated with increased insulin concentrations. This effect appears to be due to a blockade of ATP-sensitive potassium channel activity via a different binding site to that of glibenclamide.Keywords
This publication has 22 references indexed in Scilit:
- K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive ratEuropean Journal of Pharmacology, 1994
- Inhibition of K+ Channels and Stimulation of Insulin Secretion by the Sulfonylurea, Glimepiride, in Relation to Its Membrane Binding in Pancreatic IsletsPharmacology, 1994
- The Pharmacology of ATP-Sensitive Potassium ChannelsAnnual Review of Pharmacology and Toxicology, 1993
- The sulfonylurea receptorBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
- Modulation of [3H]glibenclamide binding to cardiac and insulinoma membranesEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- Two binding sites for [3H]glibenclamide in the rat brainBrain Research, 1991
- Expedient synthesis and biochemical properties of an [125I]-labeled analogue of glyburide, a radioligand for ATP-inhibited potassium channelsJournal of Medicinal Chemistry, 1990
- Identification of high and low (GTP-sensitive) affinity [ 3 H]glibenclamide binding sites in cardiac ventricular membranesBiochemical and Biophysical Research Communications, 1990
- Protein phosphorylation is required for diazoxide to open ATP‐sensitive potassium channels in insulin (RINm5F) secreting cellsFEBS Letters, 1989
- GliclazideDrugs, 1984